# A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

> **NCT03219268** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 277 (actual)

## Conditions studied

- Advanced Solid Tumors
- Hematologic Neoplasms
- Ovarian Cancer
- HER2-positive Advanced Solid Tumors
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Cholangiocarcinoma
- Cervical Cancer
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** tebotelimab 1 mg
- **BIOLOGICAL:** tebotelimab 3 mg
- **BIOLOGICAL:** tebotelimab 10 mg
- **BIOLOGICAL:** tebotelimab 30 mg
- **BIOLOGICAL:** tebotelimab 120 mg
- **BIOLOGICAL:** tebotelimab 300 mg
- **BIOLOGICAL:** tebotelimab 400 mg
- **BIOLOGICAL:** tebotelimab 600 mg
- **BIOLOGICAL:** tebotelimab 800 mg
- **BIOLOGICAL:** tebotelimab 1200 mg
- **BIOLOGICAL:** margetuximab

## Key facts

- **NCT ID:** NCT03219268
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-18
- **Primary completion:** 2023-02-08
- **Final completion:** 2023-02-08
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219268, "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03219268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*